

# ASX Release

---

## SUDA PHARMACEUTICALS: BUSINESS DEVELOPMENT UPDATE

### Highlights

- **Refocused BD Strategy**
- **12 term sheets in negotiation**
- **SUDA to invest in High Value US Market**
- **Focus on commercialisation**

**PERTH, AUSTRALIA - 16 JULY 2018:** On the 9<sup>th</sup> April 2018, SUDA announced the appointment of David Phillips to the SUDA board. David's breadth of experience proved invaluable and allowed SUDA to refocus its Business Development activities which was aimed at improving deal flow, building a global brand and creating multiple transaction leads.

SUDA has also decided to focus its BD strategy on the US market which is the world's largest market and enjoys premium valuations and margins.

On the back of these changes, the Company has seen a significant improvement in target generation and potential new transactions to the extent that SUDA currently has 12 potential transactions at a term sheet stage (or more). In addition to this, SUDA has in excess of 30 active leads and discussions at the technical level, all of which are subject to non-disclosure agreements.

Our commercial partners, Teva and Eddingpharm, are continuing to progress their respective projects through the regulatory phase towards commercialisation. We are also working with our Pfizer team to move their project to the next stage.

ArTiMist® is progressing through the Australian Regulatory process with the TGA and we have agreement to meet with the WHO to gain further clarification on key questions raised by one of our potential commercial partners.

SUDA's board understands the need to focus on growth and revenue generation and the importance of deal closure to build shareholder value.



**Further information:**

**STEPHEN CARTER**

**CHIEF EXECUTIVE OFFICER / MANAGING DIRECTOR**

**SUDA Pharmaceuticals Ltd**

Tel: +61 8 6142 5555

[sjcarter@sudapharma.com](mailto:sjcarter@sudapharma.com)

**NOTES TO EDITORS:**

**About SUDA Pharmaceuticals Ltd**

SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e.: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist is marketed in the USA and SUDA has rights to the product outside of the US and Canada. SUDA has submitted a Marketing Authorisation Application to the Australian Therapeutic Goods Administration for ArTiMist®, its novel sublingual malaria treatment for children. In a Phase III trial, ArTiMist was shown to be superior to intravenous quinine. Other products in development include oral sprays for the treatment of migraine headache, chemotherapy-induced nausea and vomiting, erectile dysfunction, PAH, epileptic seizures and pre-procedural anxiety. For more information, visit [www.sudapharma.com](http://www.sudapharma.com)